AlloSource's AlloWrap DS amniotic membrane moved to high-cost reimbursement category

AlloSource®, one of the nation's largest providers of cartilage, cellular, bone, skin and soft-tissue allografts for use in surgical procedures and wound care to advance patient healing, today announced that AlloWrap® DS, its double-sided human amniotic membrane allograft, has been moved to the high-cost reimbursement category.

"Reimbursement helps ensure that our allografts reach doctors and their patients," said Kimberly French, Director of Marketing for AlloSource. "AlloWrap's high-cost reimbursement category is an exciting landmark as we navigate the changing healthcare landscape to expand the reach of our products."

AlloWrap DS was recently reassigned to the high-cost category for skin substitutes as part of a Noridian Medicare Administrative Contract in Alaska, Arizona, Idaho, Montana, North Dakota, Oregon, South Dakota, Utah, Washington and Wyoming.

AlloWrap DS is used in primary and revision surgical applications for nerves, tendons, vessels and other tissues. Amniotic membrane is rich with bioactive proteins that aid in wound healing. In addition, amniotic membrane is immune-privileged and has been shown to have anti-microbial characteristics. AlloWrap DS is designed to provide a biological barrier and the stable, thin, strong membrane barrier conforms and settles within surrounding tissues and remains in the site for over eight weeks.

AlloSource has also entered into a partnership with Stryker® Corporation for distribution of AlloWrap DS, which builds on the direct distribution already in place.